CA2883703C - Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin - Google Patents

Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin Download PDF

Info

Publication number
CA2883703C
CA2883703C CA2883703A CA2883703A CA2883703C CA 2883703 C CA2883703 C CA 2883703C CA 2883703 A CA2883703 A CA 2883703A CA 2883703 A CA2883703 A CA 2883703A CA 2883703 C CA2883703 C CA 2883703C
Authority
CA
Canada
Prior art keywords
bone
cancer
osteosarcoma
cells
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2883703A
Other languages
English (en)
French (fr)
Other versions
CA2883703A1 (en
Inventor
Forrest H. Anthony
Matthew M Parris
Edwin J. Thomas
Quangtao ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eleison Pharmaceuticals LLC
Original Assignee
Eleison Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleison Pharmaceuticals LLC filed Critical Eleison Pharmaceuticals LLC
Publication of CA2883703A1 publication Critical patent/CA2883703A1/en
Application granted granted Critical
Publication of CA2883703C publication Critical patent/CA2883703C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2883703A 2012-09-04 2013-09-04 Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin Active CA2883703C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261743398P 2012-09-04 2012-09-04
US61/743,398 2012-09-04
PCT/US2013/058025 WO2014039533A2 (en) 2012-09-04 2013-09-04 Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin

Publications (2)

Publication Number Publication Date
CA2883703A1 CA2883703A1 (en) 2014-03-13
CA2883703C true CA2883703C (en) 2021-10-19

Family

ID=50187920

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2883703A Active CA2883703C (en) 2012-09-04 2013-09-04 Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin

Country Status (11)

Country Link
US (1) US11291644B2 (da)
EP (1) EP2892524B1 (da)
JP (1) JP2015530387A (da)
CN (3) CN115414384A (da)
CA (1) CA2883703C (da)
DK (1) DK2892524T3 (da)
ES (1) ES2848025T3 (da)
HK (1) HK1212593A1 (da)
MX (1) MX2015002842A (da)
PL (1) PL2892524T3 (da)
WO (1) WO2014039533A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
PL2307459T3 (pl) 2008-07-08 2015-05-29 Oncomed Pharm Inc Czynniki wiążące receptor Notch1 i sposoby ich stosowania
CN115414384A (zh) 2012-09-04 2022-12-02 埃莱森制药有限责任公司 用顺铂脂质复合物预防癌症的肺部复发
US10555967B2 (en) 2013-07-08 2020-02-11 International Dehydrated Foods, Inc. Compositions prepared from poultry and methods of their use
US11478504B2 (en) 2013-07-08 2022-10-25 International Dehydrated Foods, Inc. Compositions and methods for preventing/treating metabolic syndrome
WO2015134627A1 (en) * 2014-03-07 2015-09-11 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch1 antibodies
CN109568336B (zh) * 2018-12-29 2021-10-08 江苏靶标生物医药研究所有限公司 一种铂类化合物和硫酸软骨素的组合物及其应用
EP4304654A1 (en) * 2021-03-11 2024-01-17 Kalocyte, Inc. Compositions and methods for removing bio-synthetic nano-particles from bodily fluids

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (da) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US5435989A (en) 1982-03-30 1995-07-25 Vestar, Inc. Method of targeting a specific location in a body
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GR79615B (da) 1982-10-08 1984-10-31 Glaxo Group Ltd
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4590001A (en) 1983-03-28 1986-05-20 Stjernholm Rune L Platinum bound to transferrin for use in the treatment of breast tumors
USRE33071E (en) 1983-03-28 1989-09-26 Platinum bound to transferrin for use in the treatment of breast tumors
US4572425A (en) 1983-08-01 1986-02-25 Russell William S Reusable container
EP0153955A1 (en) 1983-09-06 1985-09-11 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
CA1270198A (en) 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
JPH0665648B2 (ja) 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5117022A (en) 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5041581A (en) 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
WO1989000846A1 (en) 1987-07-29 1989-02-09 The Liposome Company, Inc. Method for size separation of particles
IL83380A (en) 1987-07-30 1991-04-15 Teva Pharma Stable aqueous cisplatin solutions
EP0331504B1 (en) 1988-03-04 1992-06-10 Takeda Chemical Industries, Ltd. Liposome composition
US5141751A (en) 1988-06-29 1992-08-25 Daiichi Pharmaceutical Co., Ltd. Lipid membrane structures
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
EP0551169A1 (en) 1992-01-10 1993-07-14 Takeda Chemical Industries, Ltd. Liposome composition and production thereof
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
CN1088777A (zh) 1992-12-18 1994-07-06 丛繁滋 用于癌病灶直接给药的化疗药物制剂的制备方法
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5780054A (en) 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
EP0896816A4 (en) 1996-02-26 2002-06-12 Daiichi Seiyaku Co LIPOSOME AND LIPOSOME DISPERSION
DE69722793T2 (de) 1996-04-26 2004-05-19 Genaera Corp. Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren
ES2208946T3 (es) 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. Liposomas que contienen un compuesto de cisplatino.
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
AU7711096A (en) 1996-12-03 1998-06-29 Rijsuniversiteit Utrecht Cisplatinum comprising pharmaceutical
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
EP0954283B1 (en) 1996-12-30 2007-03-21 Battelle Memorial Institute Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation
DE69828038T2 (de) 1997-02-05 2005-11-03 Pharmacia & Upjohn Co., Kalamazoo Lipidkomplexe von sehr unlöslichen platinkomplexen
FR2759293B1 (fr) 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
US6630168B1 (en) 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US7348025B2 (en) 1997-09-23 2008-03-25 Research Development Foundation Small particle liposome aerosols for delivery of anticancer drugs
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
ES2156506B1 (es) 1998-10-14 2002-03-01 Sumitomo Chemical Co Metodo para la produccion de oxido de propileno.
CZ20011581A3 (cs) 1998-11-12 2001-12-12 Frank G. Pilkiewicz Systém pro podávání bioaktivní sloučeniny inhalací
US20050074499A1 (en) 1999-03-17 2005-04-07 Mitsubishi Chemical Corporation Ligand-bonded complex
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
AU780454B2 (en) 1999-06-03 2005-03-24 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
CA2389147A1 (en) 1999-11-05 2001-05-10 Seed Capital Investment-2 (Sci-2) B.V. Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
CN1167461C (zh) 1999-12-04 2004-09-22 研究发展基金会 吸入治疗的二氧化碳增强
WO2001056548A2 (en) 2000-02-04 2001-08-09 Lipoxen Technologies Limited Liposomes composition produced by a dehydration-rehydration process
CA2402613A1 (en) 2000-03-29 2001-10-04 Igor Gonda Cationic liposomes
WO2001082892A2 (de) 2000-05-02 2001-11-08 Pharmacept Gmbh Wirkstoffhaltige liposome
US6998393B2 (en) 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
ATE309787T1 (de) 2000-06-30 2005-12-15 Inex Pharmaceuticals Corp Verbesserte liposomale camptothecine und deren verwendungen
JP2004537501A (ja) 2001-02-01 2004-12-16 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 肺への遺伝子送達のための安定化ポリマーエアロゾル
WO2002085385A2 (en) 2001-04-23 2002-10-31 Nucryst Pharmaceuticals Corp. Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa
ATE322249T1 (de) 2001-05-18 2006-04-15 Chiron Corp System zur abgabe einer tobramycin-formulierung
AU2002323151A1 (en) 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
AU2002323266B2 (en) 2001-08-20 2008-04-24 Transave, Inc. Method for treating lung cancers
CA2457148A1 (en) 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
US20030224039A1 (en) 2002-03-05 2003-12-04 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
JP3415131B1 (ja) 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040022842A1 (en) 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
CN1681478A (zh) 2002-08-02 2005-10-12 川塞夫有限公司 铂聚集体及其制备方法
MXPA05004580A (es) 2002-10-29 2005-07-26 Transave Inc Liberacion sostenida de anti - infecciosos.
AU2003298738A1 (en) 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
JP5032849B2 (ja) 2004-01-14 2012-09-26 ギリアード サイエンシーズ， インコーポレイテッド 薬物送達に有用な脂質ベースの分散物
CA2559722A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US20070065522A1 (en) 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
US8221739B2 (en) * 2004-04-29 2012-07-17 Botanic Oil Innovations, Inc. Method of cancer treatment
AU2005245018A1 (en) 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20060246124A1 (en) 2004-11-08 2006-11-02 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
JP2008523151A (ja) 2004-12-14 2008-07-03 トランセイブ， インク． 生理活性物質を含む脂質粒子、その調製法及び使用法
WO2006113181A2 (en) * 2005-04-08 2006-10-26 University Of Florida Research Foundation, Inc. Stem-like cells in bone sarcomas
US20090130194A1 (en) * 2005-11-08 2009-05-21 Transave, Inc. Methods of Treating Cancer with High Potency Lipid-Based Platinum Compound Formulations Administered Intravenously
WO2007056264A2 (en) 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064658A2 (en) 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
GR20060100144A (el) 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
SG176064A1 (en) * 2009-05-14 2011-12-29 Oatmeal Biotechnologies Group L L C Platform technologies for spontaneously occurring diseases
NZ602000A (en) 2010-02-22 2015-05-29 Edge Therapeutics Inc Methods and compositions to treat hemorrhagic conditions of the brain
EP2593118A2 (en) * 2010-07-16 2013-05-22 Epeius Biotechnologies Corporation Targeted nanoparticles for cancer and other disorders
CN115414384A (zh) 2012-09-04 2022-12-02 埃莱森制药有限责任公司 用顺铂脂质复合物预防癌症的肺部复发

Also Published As

Publication number Publication date
HK1212593A1 (zh) 2016-06-17
EP2892524A2 (en) 2015-07-15
US11291644B2 (en) 2022-04-05
JP2015530387A (ja) 2015-10-15
DK2892524T3 (da) 2021-01-25
CN105025904A (zh) 2015-11-04
PL2892524T3 (pl) 2021-10-25
EP2892524A4 (en) 2016-07-06
CA2883703A1 (en) 2014-03-13
CN115414384A (zh) 2022-12-02
US20140065205A1 (en) 2014-03-06
CN112451486A (zh) 2021-03-09
ES2848025T3 (es) 2021-08-05
EP2892524B1 (en) 2020-11-25
WO2014039533A3 (en) 2015-07-16
MX2015002842A (es) 2015-08-12
WO2014039533A2 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
CA2883703C (en) Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
Fazil et al. Bisphosphonates: therapeutics potential and recent advances in drug delivery
Bacci et al. Neoadjuvant chemotherapy for extremity osteosarcoma: preliminary results of the Rizzoli's 4th study
JP6400479B2 (ja) 肺疾患特異的治療剤
US7638272B2 (en) Cancer therapy sensitizer
US8551967B2 (en) Formulations with anti-tumour action
KR20070097495A (ko) 섬유화 억제를 위한 약물 담체 및 약물 담체 키트
KR20110132446A (ko) 키나아제 단백질 결합 억제제
CN109069470B (zh) 特定苯并二氢呋喃类木脂素于抑制乳癌细胞转移之用途
JP2016528217A (ja) 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
Ledwitch et al. Taxol: efficacy against oral squamous cell carcinoma
TWI725947B (zh) 巴豆酯組成物及用於治療或減少血球細胞減少期間之用途
MX2009001233A (es) Metodos, composiciones y articulos de manufactura para contribuir al tratamiento de canceres.
Todd et al. LiF@ SiO 2 nanocapsules for controlled lithium release and osteoarthritis treatment
Weber et al. Renal cell carcinoma bone metastasis: epidermal growth factor receptor targeting.
US20150297623A1 (en) Methods for treatment of primary cancer and cancer metastasis
Lan et al. Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers
Karita et al. The antitumor effect of liposome-encapsulated cisplatin on rat osteosarcoma and its enhancement by caffeine
Xu et al. Targeting type H vessels in bone‐related diseases
WO2023062516A1 (en) 2-deoxy-d-glucose for use in disease therapy
Zhang et al. Preparation and evaluation of inhalable S-allylmercapto-N-acetylcysteine and nintedanib co-loaded liposomes for pulmonary fibrosis
US20120171181A1 (en) Compositions and minimally invasive methods for treating cancer
Curtis et al. Evaluation of Parathyroid Hormone and Zoledronic Acid in Promoting Bone Healing after Stereotactic Radiation Therapy for Local Control of Osteosarcoma in an Orthotopic Rat Model
US20090304597A1 (en) Use of an Active Biological Substance in Abnormal Cellular and Viral Membrane Physiologies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180830